



NEWS RELEASE

CareDx to Present Clinical Abstracts Containing New Data at the 2016 ISHLT

On AlloMap[®] & AlloSure[™] in heart transplant patients

Brisbane, CA —April 28, 2016—CareDx, Inc. (Nasdaq: CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced clinical presentations for the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) being held April 27 – 30, 2016 in Washington, DC.

A total of eight clinical abstracts featuring CareDx technology will be presented, including the initial analysis of cell-free DNA in the Outcomes AlloMap Registry (D-OAR) Study in heart transplant patients undergoing surveillance of rejection. Additional data are being presented by clinicians on the impact of cytomegalovirus infection on gene expression profiling scores over time.

CareDx is also sponsoring a lunchtime panel symposium on Friday, April 29 on the application of genomics in transplant patients. The symposia will moderated by Doctors. Jon Kobashigawa and Kiran Khush of Cedars-Sinai and the Stanford University Medical Center respectively, and features additional speakers from the US and Europe.

“There’s a great deal of interest in the new cell-free DNA technologies, and the initial analysis in heart transplant patients helps guide clinical development,” said James Yee, MD PhD, Chief Medical Officer of CareDx. “As we gain further clinical insights in the biologic interpretation of AlloSure, we and our collaborators will be able to make advancements in clinical utility.”

Additional information on CareDx presentations and data can be found at the CareDx booth at ISHLT (Booth #911) and through the conference website: <http://www.isHLT.org/meetings/annualMeeting.asp>

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The company markets AlloMap[®], a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure[™], a next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation.

CareDx, with its presence through Olerup AB, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP[®], a set of HLA typing is used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation; and XM-ONE[®], the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit: www.CareDx.com.

Media Contacts – CareDx

Molly Martell, Senior Director, Marketing

T: +1 415-728-6307

E: [mmartell@caredx.com](mailto:mmartell@ caredx.com)

Media Contacts - Investor

Jamar Ismail, Vice President

Westwicke Partners, LLC

T: +1 415-513-1282

E: jamar.ismail@westwicke.com

Forward Looking Statements

In addition to the historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks related to our plans and ability to develop and commercialize new solutions, including cell-free DNA solutions for heart and kidney transplant recipients. These factors, together with those that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.